High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
Investigational Drug Branch, National Cancer Institute, Bethesda, MD 20892.
D R
DR
Parkinson
M
M
Sznol
D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D004334:Drug Administration Schedule; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation; D016896:Treatment Outcome
D007376:Interleukin-2